Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Approche pharmacogénétique de la réponse aux antipsychotiques chez les schizophrènes. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
1994 · External reference
Association between clozapine response and allelic variation in 5-HT2A receptor gene
10.1016/s0140-6736(95)92168-0 · 1995 · External reference
Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine
10.1038/sj.mp.4000348 · 1998 · External reference
Pharmacogenetic prediction of clozapine response
10.1016/s0140-6736(00)02221-2 · 2000 · External reference
Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia
10.1016/s0893-133x(98)00114-6 · 1999 · External reference
A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia
10.1038/sj.mp.4000736 · 2000 · External reference
Association analysis of the genetic variants of the N-methyl d-aspartate receptor subunit 2b (NR2b) and treatment-refractory schizophrenia in the Chinese
10.1159/000071211 · 2003 · External reference
The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups
10.1182/blood.v86.10.3835.bloodjournal86103835 · 1995 · External reference
Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor
10.1093/hmg/ddg055 · 2003 · External reference
Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia
10.1002/(sici)1096-8628(20000403)96:2<187::aid-ajmg13>3.0.co;2-8 · 2000 · External reference
The global assessment scale: a product for measuring overall severity of psychiatric disturbance
10.1001/archpsyc.1976.01770060086012 · 1976 · External reference
A diagnostic interview: the schedule for affective disorders and schizophrenia
10.1001/archpsyc.1978.01770310043002 · 1978 · External reference
Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia
10.1097/00041444-200112000-00007 · 2001 · External reference
Novel antipsychotics
10.1016/s0065-7743(08)60875-1 · 1993 · External reference
Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia
10.1016/s0006-3223(98)00134-6 · 1998 · External reference
T102C polymorphism in the 5-HT2A gene and schizophrenia: relation to phenotype and drug response variability
1999 · External reference
Neuregulin genotype and medication response in Finnish patients with schizophrenia
10.1097/00001756-200411150-00017 · 2004 · External reference
Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine
10.1001/archpsyc.1988.01800330013001 · 1988 · External reference
The positive and negative syndrome scale (PANSS): rationale and standardisation
10.1192/s0007125000291514 · 1989 · External reference
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
10.1038/sj.mp.4001494 · 2004 · External reference
Combination of dopamine D2 receptor gene polymorphisms as a possible predictor of treatment-resistance to dopamine antagonists in schizophrenic patients
10.1016/s0278-5846(03)00151-9 · 2003 · External reference
Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia
10.1038/sj.mp.4000749 · 2000 · External reference
Association of risperidone treatment response with a polymorphism in the 5-HT2A receptor gene
10.1176/appi.ajp.159.9.1593 · 2002 · External reference
Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function
10.1017/s1461145704004389 · 2004 · External reference
Dopamine D3 receptor Ser9Gly polymorphism and risperidone response
10.1097/01.jcp.0000150226.84371.76 · 2005 · External reference
Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders
10.1097/00041444-199210000-00003 · 1992 · External reference
Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C)
10.1006/geno.1995.1042 · 1995 · External reference
No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population
10.1097/00001756-199901180-00011 · 1999 · External reference
Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine
10.1176/ajp.153.8.1092 · 1996 · External reference
Distribution and characterization of [3H]mesulergine binding in human brain postmortem
10.1016/s0924-977x(99)00045-0 · 1999 · External reference
Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients
10.1016/s0893-133x(98)00007-4 · 1998 · External reference
The D2 dopamine receptor gene: a review of association studies in alcoholism and phenotypes
10.1016/s0741-8329(97)00175-4 · 1998 · External reference
NQO2 gene is associated with clozapine-induced agranulocytosis
10.1046/j.1399-0039.2003.00133.x · 2003 · External reference
The brief psychiatric rating scale
10.2466/pr0.1962.10.3.799 · 1962 · External reference
Pharmacogenomics of psychiatric disorders
10.1016/s0165-6147(00)01603-5 · 2001 · External reference
Differential expression of the “C” and “T” alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics
10.1002/jnr.10173 · 2002 · External reference
Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism
10.1016/s0140-6736(02)08913-4 · 2002 · External reference
Polymorphism of the promoter region of the seroton in 5-HT(2C) receptor gene and clozapine-induced weight gain
10.1176/appi.ajp.160.4.677 · 2003 · External reference
Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response
10.1016/j.euroneuro.2004.07.001 · 2005 · External reference
Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor
10.1097/00001756-199705260-00040 · 1997 · External reference
Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene
10.1176/appi.ajp.158.5.802 · 2001 · External reference
Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients
10.1016/s0924-977x(99)00044-9 · 1999 · External reference
Pharmacogenetics of the clozapine response
10.1016/s0140-6736(05)74176-3 · 2000 · External reference
Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia
10.1038/sj.mp.4000511 · 1999 · External reference
Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia
10.1038/sj.mp.4000842 · 2001 · External reference
Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia
10.1007/bf02346178 · 1996 · External reference
Association between clozapine response and allelic variation in the 5-HT2C receptor gene
10.1097/00001756-199512000-00041 · 1995 · External reference
Clinical applications of pharmacogenetics in psychiatry
10.1007/s00213-002-1084-4 · 2002 · External reference
The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients
10.1097/00008571-200006000-00007 · 2000 · External reference
Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia
10.1002/ajmg.b.20045 · 2004 · External reference
Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor
10.1016/s0006-3223(01)01076-9 · 2001 · External reference
Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups
10.1182/blood.v89.11.4167 · 1997 · External reference
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
10.1038/350610a0 · 1991 · External reference
Multiple dopamine D4 receptor variants in the human population
10.1038/358149a0 · 1992 · External reference
Pharmacogenetics and the serotonin system: initial studies and future directions
10.1016/s0014-2999(00)00814-1 · 2000 · External reference
Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics
10.1046/j.1440-1819.2002.01038.x · 2002 · External reference
Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients
10.1016/j.neulet.2004.11.014 · 2005 · External reference
DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study
10.1016/s0924-977x(03)00006-3 · 2003 · External reference
Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine
10.1080/00207450590957863 · 2005 · External reference
